MicroRNA signatures in hereditary breast cancer

Breast Cancer Research and Treatment

Volumn 142, Issue 1, 2013, Pages 19-30

  Murria Estal, Rosa ^a   Palanca Suela, Sarai ^a   De Juan Jiménez, Inmaculada ^a   Egoavil Rojas, Cecilia ^b   García Casado, Zaida ^c   Juan Fita, María José ^d   Sánchez Heras, Ana Beatriz ^e   Segura Huerta, Ángel ^a   Chirivella González, Isabel ^f   Sánchez Izquierdo, Dolors ^g   Llop García, Marta ^a   Barragán González, Eva ^a   Bolufer Gilabert, Pascual ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b University General Hospital   (Spain)

^c Laboratory of Molecular Biology IVO   (Spain)

^d IVO   (Spain)

^e Allergy Service   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HEALTH RESEARCH INSTITUTE LA FE   (Spain)

Author keywords

BRCA1; BRCA2; Hereditary breast cancer; miR expression profile; Molecular markers; Mutations; Sporadic breast cancer

Indexed keywords

AURORA A KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; AURKA GENE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASSF1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84888235389     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2723-7     Document Type: Article

References (46)

1. Boyle P, Ferlay J (2004) Cancer incidence and mortality in Europe. Ann Oncol 16:481-488
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
3. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789-792
4. Ford D, Easton DF, Stratton MR, Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689
5. Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17-22
6. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al (2012) The cancer atlas network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70
7. Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986-1994
8. Consellería de Sanitat Generalitat Valenciana (2008) Cáncer Colorrectal hereditario no polipósico (CCHNP): Sindrome de Lynch. Guía de Práctica Clínica en cáncer hereditario. Plan Oncológico Comunidad Valenciana. Oficina del Plan del Cáncer. Dirección General de Salud Pública Generalitat Valenciana, pp 60-77
9. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790
10. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Wilfond B, Sauter G, Kallioniemi OP, Borg A, Trent J (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548
11. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM (2012) Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 107(4):684-694
12. Hui A, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Jurisica I, Penn LZ, Liu F (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89(5):597-606
13. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7093):834-838
14. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26(4):462-469
15. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia A, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070
16. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. doi: 10.1186/bcr2257
17. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/pdf/17c. pdf
18. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(7):e48-e72
19. Milanezi F, Carvalho S, Schmitt FC (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 8(4):417-434
20. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-1747
21. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750
22. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-5374
23. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57
24. Moelans CB, de Wegers RA, Monsuurs HN, Maess AHJ, van Diest PJ (2011) Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr) 34(5):475-482
25. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JGI, Nygren AOH, Errami A, Schouten JP, Meijer CJLM, Snijders PJF, Steenbergen RDM (2007) Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 97(10):1457-1464
26. The Breast Cancer Information Core Database, BIC. http://research.nhgri. nih.gov/bic/Member/index.shtml
27. Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 90:10325-10329
28. Esteban E, Bolufer P, Palanca S, Barragán E, Oltra S, Chirivella I, Segura A, Guillén C, Martínez E, Cuevas D, Salas D (2008) BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain). Med Clin (Barc) 130(4):121-126
29. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002-2007
30. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright (2006) MiRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34:D140-D144
31. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG (2012) DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 40:W498-W504
32. Le Cao KA, Boitard S, Besse P (2011) Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinforma 12:253
33. Chang S, Sharan SK (2012) Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget 3:5-6
34. Chang S, Wang RH, Akagi K, Kim KA, Martin KB, Cavallone L, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK (2011) Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 17(10):1275-1282
35. Swami M (2010) Cancer epigenetics: long-range silencing. Nat Rev Cancer 10:238-239
36. Lizé M, Klimke A, Dobbelstein M (2011) MicroRNA-449 in cell fate determination. Cell Cycle 10:2874-2882
37. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X, Wang E (2013) MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS ONE. doi: 10.1371/0064759
38. Kheir TB, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B, Lund AH, Friis-Hansen L (2011) MiR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer 10:29
39. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z (2012) miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett 4:1027-1032
40. Mattie MD, Benz CC, Bowers, Sensinger JK, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24
41. Ng EKO, Li R, Shin VY, Jin HC, Leung CPH, Ma ESK, Pang R, Chua D, Chu KM, Law WL, Law SYK, Poon RTP, Kwong A (2013) Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS ONE. doi: 10.1371/.005314
42. http://www.affymetrix.com/browse/products.jsp?productId=131473#1
43. Kolbert et al (2013) Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS ONE 8(1). doi: 10.1371/0052517
44. Dahlgaard J, Mazin W, Jensen T, Pøhl M, Bshara W, Hansen A, Kanisto E, Hamilton-Dutoit SK, Hansen O, Hager H, Ditzel HJ, Yendamuri S, Knudsen S (2011) Analytical variables influencing the performance of a miRNA based laboratory assay for prediction of relapse in stage I non-small cell lung cancer (NSCLC). BMC Res Notes 4:424
45. Casiano D, Woodcock J (2006) Empowering microarrays in the regulatory setting. Nat Biotechnol 24(9):1103
46. MAQC Consortium (2006) The MicroArray Quality Control (MAQC) project shows inter and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24(9):1151-1161